STOCK TITAN

Merck & Co Inc - MRK STOCK NEWS

Welcome to our dedicated news page for Merck & Co (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Merck & Co's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Merck & Co's position in the market.

Rhea-AI Summary
Merck leaders discuss efforts to address vaccine-preventable illnesses and combat vaccine hesitancy, emphasizing collaboration and equity to improve global vaccination programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Merck's KEYTRUDA receives EC approval for neoadjuvant and adjuvant treatment in resectable NSCLC in Europe, marking the first anti-PD-1/L1 therapy approved for this indication. The approval is based on positive overall survival results from the Phase 3 KEYNOTE-671 trial, showing significant improvements in OS and EFS. This milestone expands KEYTRUDA's indications to six in NSCLC and 27 overall in the EU.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Merck (MRK) receives FDA approval for WINREVAIR, a breakthrough therapy for pulmonary arterial hypertension (PAH), showing significant clinical benefits in improving exercise capacity and reducing clinical worsening events. WINREVAIR is the first FDA-approved activin signaling inhibitor therapy for PAH, offering a new treatment pathway.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.96%
Tags
fda approval
Rhea-AI Summary
The Merck Foundation, funded by Merck (NYSE:MRK), commits $11 million over six years to support healthcare in underserved communities, training 33,000 local health workers in India, Indonesia, Malaysia, and Vietnam. This builds on a previous $7 million commitment to improve access to specialty care for chronic conditions in India and Vietnam.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
none
-
Rhea-AI Summary
Merck's Phase 3 KEYLYNK-006 trial evaluating KEYTRUDA in combination with LYNPARZA did not meet primary endpoints for certain patients with metastatic nonsquamous NSCLC. Safety profiles were consistent, and further data evaluation is ongoing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
clinical trial
-
Rhea-AI Summary
Merck (MRK) announces positive data from Phase 3 trials of V116, a potential pneumococcal conjugate vaccine for adults, at the 13th ISPPD meeting. V116 shows immunogenicity across various adult populations and higher immune responses for unique serotypes. FDA granted V116 priority review with a PDUFA date of June 17, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
none
Rhea-AI Summary
FarmSee partners with MSD Animal Health to integrate AI-based weighing technology for swine monitoring. The collaboration aims to optimize swine production globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.07%
Tags
none
-
Rhea-AI Summary
Merck's Phase 3 KEYNOTE-A18 trial with KEYTRUDA plus CRT shows significant improvement in OS for patients with high-risk locally advanced cervical cancer. The combination therapy met its primary endpoint of overall survival, demonstrating a statistically significant and clinically meaningful benefit compared to CRT alone. The safety profile was consistent with previous studies, with no new safety signals identified. These results support the FDA's approval of KEYTRUDA in combination with CRT for the treatment of patients with FIGO Stage III-IVA cervical cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
none
-
Rhea-AI Summary
Merck (MRK) reaffirms its commitment to reducing the global burden of HPV-related diseases by announcing plans to develop a new multi-valent HPV vaccine and conduct clinical trials for a single-dose regimen of GARDASIL 9. The company aims to impact the burden of certain HPV-related cancers and diseases by expanding protection and supply capacity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
clinical trial
Rhea-AI Summary
Merck (MRK) acquires Harpoon Therapeutics, broadening its oncology pipeline with T-cell engagers like MK-6070 targeting DLL3. MK-6070 is in Phase 1/2 trials for small cell lung cancer (SCLC) and neuroendocrine tumors. Merck records a $650 million charge for the acquisition, impacting non-GAAP EPS by $0.26 per share for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
Merck & Co Inc

NYSE:MRK

MRK Rankings

MRK Stock Data

333.68B
2.53B
0.07%
78.61%
0.66%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Kenilworth

About MRK

Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of whom it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada.